Intranasal Route For Brain Targeting Of Naringenin- A Potential Antioxidant Drug For The Treatment Of Parkinson’s Disease Using Nano-Emulsion As The Drug Delivery Carrier

Abstract

The neurodegenerative illness known as Parkinson's disease (PD) causes a shortage of dopamine in the brain's nigrostriatal region. One cause of PD is oxidative stress. The flavonoid naringenin (NAR) has been proven to be helpful in animal models of Parkinson's disease (PD). The purpose of this study is to develop a nasal-to-brain transport (PD) Nanoemulsion (NE) of vitamin E-loaded naringenin (NRG) for the treatment of Parkinson's disease. To evaluate the efficacy of the enhanced NE in PD, many behavioral tests were performed in a rat model. The findings from the present research suggest that NRG administered using a new noninvasive intranasal delivery technology may be effective in the treatment of PD-related symptoms. The purpose of this study is to develop a nasal-to-brain transport (PD) Nanoemulsion (NE) of vitamin E-loaded naringenin (NRG) for the treatment of Parkinson's disease. To evaluate the efficacy of the enhanced NE in PD, many behavioral tests were performed in a rat model.